Montecito Bank & Trust Has $272,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Montecito Bank & Trust lifted its stake in AstraZeneca PLC (NASDAQ:AZN) by 34.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,156 shares of the company’s stock after purchasing an additional 1,066 shares during the quarter. Montecito Bank & Trust’s holdings in AstraZeneca were worth $272,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. McClarren Financial Advisors Inc. boosted its holdings in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new position in AstraZeneca in the 3rd quarter worth approximately $28,000. Ashton Thomas Securities LLC purchased a new position in AstraZeneca during the 3rd quarter worth approximately $45,000. Albion Financial Group UT raised its stake in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares during the period. Finally, Hollencrest Capital Management lifted its holdings in shares of AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock valued at $54,000 after purchasing an additional 192 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $69.06 on Friday. The firm has a market cap of $214.16 billion, a P/E ratio of 33.04, a PEG ratio of 1.13 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock’s 50-day moving average is $66.33 and its two-hundred day moving average is $74.24.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.87 earnings per share. Analysts predict that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.